Abstract
Neurodegenerative disorders (NDDs) are characterized by the progressive loss of structure or neuron function, often associated with neuronal death. Treatments for neurodegenerative diseases only address symptoms without having any disease-modifying effect but serious side effects. Currently, there is no effective treatment for NDDs. This is due to the poor flow of drugs to the blood-barrier brain (BBB) which does not allow macromolecules like proteins and peptides to pass through it. Targeted drug delivery to the central nervous system (CNS) for the diagnosis and treatment of NDDs, such as Alzheimer’s disease (AD), is restricted due to the limitations posed by the BBB as well as opsonization by plasma proteins in the systemic circulation and peripheral side-effects. Nanotechnology thereby presents a broad approach for transporting molecules through the BBB, thus allowing the entry of substances acting directly on the site affected by the disease. The aim of this review is to outline current strategies in nanotechnology for treating Alzheimer’s and Parkinson’s diseases.
Keywords: Alzheimer’s disease (AD), astrocyte, Blood-brain barrier (BBB), glial cell, Parkinson’s disease (PD), nanotechnology, drug delivery, nanoparticle (NP), liposome, dendrimer, quantum dot, nanocarrier, nanoliposome, nanomicelle.
Current Pharmaceutical Design
Title:Alzheimer’s Disease and Parkinson’s Disease: A Review of Current Treatment Adopting a Nanotechnology Approach
Volume: 24 Issue: 1
Author(s): Adriana Trompetero, Aldemar Gordillo, Mora Carolina del Pilar, Velasquillo María Cristina and Rosa Helena Bustos Cruz*
Affiliation:
- Universidad de la Sabana, Faculty of Medicine, Therapeutic Evidence Group, Chía,Colombia
Keywords: Alzheimer’s disease (AD), astrocyte, Blood-brain barrier (BBB), glial cell, Parkinson’s disease (PD), nanotechnology, drug delivery, nanoparticle (NP), liposome, dendrimer, quantum dot, nanocarrier, nanoliposome, nanomicelle.
Abstract: Neurodegenerative disorders (NDDs) are characterized by the progressive loss of structure or neuron function, often associated with neuronal death. Treatments for neurodegenerative diseases only address symptoms without having any disease-modifying effect but serious side effects. Currently, there is no effective treatment for NDDs. This is due to the poor flow of drugs to the blood-barrier brain (BBB) which does not allow macromolecules like proteins and peptides to pass through it. Targeted drug delivery to the central nervous system (CNS) for the diagnosis and treatment of NDDs, such as Alzheimer’s disease (AD), is restricted due to the limitations posed by the BBB as well as opsonization by plasma proteins in the systemic circulation and peripheral side-effects. Nanotechnology thereby presents a broad approach for transporting molecules through the BBB, thus allowing the entry of substances acting directly on the site affected by the disease. The aim of this review is to outline current strategies in nanotechnology for treating Alzheimer’s and Parkinson’s diseases.
Export Options
About this article
Cite this article as:
Trompetero Adriana , Gordillo Aldemar, del Pilar Carolina Mora , Cristina María Velasquillo and Bustos Cruz Helena Rosa*, Alzheimer’s Disease and Parkinson’s Disease: A Review of Current Treatment Adopting a Nanotechnology Approach, Current Pharmaceutical Design 2018; 24 (1) . https://dx.doi.org/10.2174/1381612823666170828133059
DOI https://dx.doi.org/10.2174/1381612823666170828133059 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Application of Proteomic Tools in Modern Nanotechnological Approaches Towards Effective Management of Neurodegenerative Disorders
Current Drug Metabolism Limb-girdle Muscular Dystrophy and Therapy: Insights into Cell and Gene-based Approaches
Current Gene Therapy Therapeutic Effects of Rivastigmine and Alfa-Lipoic Acid Combination in the Charles Bonnet Syndrome: Electroencephalography Correlates
Current Clinical Pharmacology Exploring the Role of Nerve Growth Factor in Multiple Sclerosis: Implications in Myelin Repair
CNS & Neurological Disorders - Drug Targets Editorial (Thematic Issue: Metabolic Disorders, Drug Development, Drug Design and Biomarkers)
Current Pharmaceutical Design Biomarkers of Oxidative Stress and the Relationship to Cigarette Smoking
Mini-Reviews in Organic Chemistry Tyrosinase Electrochemical Biosensors Monitoring Medicinally Significant Substances
Current Medicinal Chemistry Editorial:Genomics and Epigenomics of Tumor and Aging Cells
Current Genomics The Role of Lipids and Membranes in the Pathogenesis of Alzheimer's Disease: A Comprehensive View
Current Alzheimer Research Aptiom (Eslicarbazepine Acetate) as a Dual Inhibitor of β-Secretase and Voltage-Gated Sodium Channel: Advancement in Alzheimer's Disease-Epilepsy Linkage via an Enzoinformatics Study
CNS & Neurological Disorders - Drug Targets On 11C Chemistry Reviews - Surveying and Filling the Gaps
Current Organic Chemistry Lactoferrin as a Natural Immune Modulator
Current Pharmaceutical Design Dissecting the Mechanisms of Thrombogenesis and Atherosclerosis for Neurodegenerative Disorders
Current Neurovascular Research Alzheimers Disease and Retinal Neurodegeneration
Current Alzheimer Research Insights into the Design of p97-targeting Small Molecules from Structural Studies on p97 Functional Mechanism
Current Medicinal Chemistry Butyrylcholinesterase: A Multifaceted Pharmacological Target and Tool
Current Protein & Peptide Science Inhibitors of Myostatin- and Proteasome-Dependent Signaling for Attenuating Muscle Wasting
Recent Patents on Regenerative Medicine Effects of Coenzyme Q and Creatine Supplementation on Brain Energy Metabolism in Rats Exposed to Chronic Cerebral Hypoperfusion
Current Alzheimer Research Histological and Direct Evidence for the Role of Complement in the Neuroinflammation of AD
Current Alzheimer Research Impaired Neurovascular Coupling in the APPxPS1 Mouse Model of Alzheimer’s Disease
Current Alzheimer Research